Judith M. Orvos, ELS

a BELS-certified medical writer and editor, and an editorial consultant for Contemporary OB/GYN

Articles by Judith M. Orvos, ELS

A drug that is low cost and easy to administer may help prevent maternal deaths, according to results of a randomized clinical trial. Plus: Does air pollution affect menstrual regularity? Also: According to a statement published by the American Heart Association (AHA), breast cancer patients may be at increased risk of cardiovascular disease (CVD).

Results of a study of fetal ultrasounds show that maternal obesity has an impact on fetal growth as early as 32 weeks’ gestation. Plus: Breast cancer risks increased by 21% in women who consumed more than 9 g of processed meat per day, according to a published study. Also: Does prenatal use of topiramate increase risk of cleft palate?

A systematic review and meta-analysis suggests that in pregnancies conceived via assisted reproduction, risk of adverse perinatal outcomes may be higher with donated than with autologous oocytes. Plus: Do post-cesarean antibiotics reduce infections in obese women? Also: Researchers believe they have identified the genes associated with preterm delivery.

Contemporary OB/GYN’s Editor-in-Chief, Dr Charles J. Lockwood, was honored by the Society for Maternal-Fetal Medicine (SMFM) with a Lifetime Achievement Award at the 37th Annual Pregnancy Meeting in Las Vegas. SMFM President Dr Mary Norton said that Dr. Lockwood was selected “because he really has had a remarkable career.”

A study examines whether computer-assisted detection on mammography provides sufficient benefit for the cost. Plus: Do first-time pregnancy cesarean deliveries increase the preterm birth in subsequent pregnancies. And, is conventional wisdom surrounding pregnancy and cancer accurate?

More than 30% of injuries during robotic surgery are related to operator error or robot failure but the majority of problems are not associated with the technology. So says a retrospective review of complications of robotic surgery reported to the US Food and Drug Administration (FDA) Manufacturer and User Facility Device Experience (MAUDE) database. The findings were presented at the 42nd AAGL Global Congress on Minimally Invasive Gynecology in Washington, DC.